ChemicalBook > Product Catalog >Biochemical Engineering >Amino Acids and Derivatives >Alanine derivatives >Sofosbuvir

Sofosbuvir

Sofosbuvir Suppliers list
Company Name:Yangzhou Crownyoung Chemical Technology Co.,Ltd.  Gold
Tel:+86-514-87325376 +86-514-87180828
Email:cy@crownyoung.com
Company Name:ChongQing Conscience Pharmaceuticals Ltd.  Gold
Tel:+86-023- 68549356 023-68548079
Email:clive.yang@consciencepharma.com
Company Name:Changzhou Fang Nan Medical Technology Co., Ltd.  Gold
Tel:0519-85283268
Email:sales@alnovapharm.com
Company Name:MedChemexpress LLC  Gold
Tel:609-228-6898
Email:sales@medchemexpress.cn
Company Name:Jinan Kane Pharmaceutical Technology Co., Ltd.  Gold
Tel:0531-88603458 18678658680
Email:85633700@qq.com
Sofosbuvir Basic information
Oral drug for hepatitis c
Product Name:Sofosbuvir
Synonyms:GS-7977;N-[[P(S),2'R]-2'-Deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-L-alanine 1-methylethyl ester;PSI 7977;sofosbuvir;GS-7977/sofosbuvir;sofosbuvir, PSI7977;(S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-Methyltetrahydrofuran-2-yl)Methoxy)(phenoxy)phosphoryl)aMino)propanoate;PSI-7977 Discontinued
CAS:1190307-88-0
MF:C22H29FN3O9P
MW:529.4525242
EINECS:11-000-0
Product Categories:PSI7977;Pharmaceutical intermediate;API;Inhibitors
Mol File:1190307-88-0.mol
Sofosbuvir Structure
Sofosbuvir Chemical Properties
density 1.41
Safety Information
MSDS Information
Sofosbuvir Usage And Synthesis
Oral drug for hepatitis cSofosbuvir is also called sovaldi, is the world's first oral drug for hepatitis c, was approved one of the most important new drugs in the United States in 2013. When used in a specific therapy for chronic hepatitis c genotype, it can eliminate the traditional injection drug interferon (IFN) in demand, successful developed by the world's largest manufacturer of anti-hiv drugs - gilead sciences company in the United States, its English name is Sofosbuvir, Sovaldi, its global sales peak might exceed $10 billion.
On December 6, 2013, the United States food and drug administration (FDA) approved sofosbuvir (Sovaldi) for the treatment of chronic hepatitis c virus (HCV) infection. Sofosbuvir is first used in the treatment of certain types of HCV infection without the need for safe and effective drugs at the same time the use of interferon.
Hepatitis c is a viral disease that can cause inflammation of the liver, cause liver function abate or liver failure. Most of the patients with HCV infection until liver damage becomes more obvious symptoms, this process may take several years. Some chronic HCV infection, many years later, there will be a scar and cirrhosis of the liver and can cause bleeding, jaundice (eyes or skin yellow), liver ascites, complications such as infection or liver cancer. According to the centers for disease control and prevention of information, about 3.2 million Americans have hepatitis c virus (HCV) infection.
Sofosbuvir is a kind of nucleotide analogue inhibitors, it can block a specific protein, which is required for the hepatitis c virus replication. Sofosbuvir is used as an antiviral combined treatment of chronic HCV infection. There are several different types of HCV infection. Based on the type of patients with HCV infection, treatment may include sofosbuvir, ribavirin or SuoFei wei and polyethylene glycol α. Ribavirin and polyethylene glycol α are also used for the treatment of HCV infection of two drugs.
Sofosbuvir is the third breakthrough treatment qualification awarded by the FDA approved drugs. If the preliminary clinical research evidence to prove that a drugs can provide patients with serious or life-threatening disease with a substantial improvement compared with the existing treatment, so the drug is the sponsor for the drug applied to the FDA for breakthrough treatments.
The United States patent validity: on March 26, 2029 (US patent no.:7964580 and 8334270), April 3, 2025 (US patent no. :7429572 and 8415322).
The above information is compiled by Chemicalbook XiaoNan .
UsagePSI-7977 is a prodrug that is metabolized to the active antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-monophosphate and is currently being investigated in phase 3 clinical trials for the t reatment of hepatitis C. Studies have profiled PSI-7977 as a nucleotide inhibitor of hepatitis C virus, exerting selective inhibitory effects towards HCV NS5B polymerase.
Sofosbuvir Preparation Products And Raw materials
Tag:Sofosbuvir(1190307-88-0) Related Product Information
AZD-8055 AZD 6244 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile Daclatasvir (BMS-790052) Etravirine (TMC125) Entinostat D-Arabinonic acid, 2-C-methyl-4,5-O-(1-methylethylidene)-,ethyl ester ((2R,3R,4R)-3-(benzoyloxy)-4-fluoro-4-methyl-5-oxotetrahydrofuran-2-yl)methyl benzoate 2'-deoxy-2'-fluoro-2'-C-methyluridine